Condition
BCG-Unresponsive Bladder Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 2 BCG-Unresponsive Bladder Cancer clinical trials that are recruiting, at sites in 2 countries (most in Russia (1), United States (1)). By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Sequential Gemcitabine Plus Docetaxel vs Gemcitabine Plus Mitomycin C for BCG-Unresponsive NMIBC
This study tests whether adding docetaxel after gemcitabine is better or worse than adding mitomycin C after gemcitabine for people with BCG-unresponsive high-grade non-muscle-invasive bladder cancer.
-
Intravesical gemcitabine followed by docetaxel for high-grade BCG-unresponsive NMIBC
This trial tests whether putting gemcitabine then docetaxel directly into the bladder can treat adults with high-grade non-muscle-invasive bladder cancer that did not respond to BCG.
Related topics
Quick answers
How many BCG-Unresponsive Bladder Cancer clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in Russia (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.